Shanghai Henlius Biotech's (HKG:2696) application for the phase 1b/2 clinical trial of HLX43 for injection in combination with Hansizhuang was approved by China's National Medical Products Administration, a Jan. 10 Hong Kong bourse filing said.
The trial is to test HLX43 in combination with Hansizhuang for the treatment of patients with advanced/metastatic solid tumors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.